1Havrda DE, Rathbun S, Scheid D. A case report of warfarin resistance due to azathioprine and review of the literature. Pharmacotherapy,2001, 21: 335-337.
2Penrod LE, Allen JB, Cabacungan LR. Warfarin resistance and enteral feedings: 2 case reports and a supporting in vitro study. Arch Phys Med Reabil, 2001, 82: 1270-1273.
4Ansell J,Hirsh J,Poller L,et al.The pharmacology and management of the vitamin K antagonists:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest,2004,126(3 Suppl):204s-233s.
5Miners JO,Birkett DJ.Cytochrome P4502C9:an enzyme of major importance in human drug metabolism[J].Br J Clin Pharmacol,1998,45(6):525-538.
6Scordo MG,Pengo V,Spina E,et al.Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance[J].Clin Pharmacol Ther,2002,72(6):702-710.
7Palkimas MP,Skinner HM,Gandhi PJ,et al.Polymorphism induced sensitivity to warfarin:a review of the literature[J].J Thromb Thrombolysis,2003,15(3):205-212.
8Furuya H,Fernandez-Salguero P,Gregory W,et al.Gennetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy[J].Pharmacogenetics,1995,5(6):389-392.
9Aithal GP,Day CP,Kesteven PJ,et al.Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarindose requirement and risk of bleeding complications[J].Lancet,1999,353(9154):717-719.
10Higashi MK,Veenstra DL,Kondo LM,et al.Association between CYP2C9 genetic variants and antcoagula tionrelated outcomes during warfarin therapy[J].JAMA,MA,2002,287(13):1690-1698.